Table 3 Moderate intensity of front-line therapy for young fit patient with mantle cell lymphoma
Regimen | Series | No. | Age(ys) Median (range) | MIPI Low/Int/High(%) | ORR (%) | CR (%) | mFU (ms) | mPFS (ms) | mOS (ms) | TRM (%) | Second malignancy(%) |
|---|---|---|---|---|---|---|---|---|---|---|---|
Bort-DA-EPOCH-R ± Bort | Dunleavy (2012) [42] | 43 | 58(41–73) | 50/37/13 | 92 | 63 | 48 | 50% (4-y PFS) | 80% (4-y OS) | na | na |
DA-EPOCH-R + vaccine | 26 | 57 (22–73) | 65/16/19 | 100 | 92 | 11ys | 24 | 104 | na | na | |
RB/RC | Armand(2016) [43] | 23 | 57 (42–69) | 70/22/9 | 96 | 96 | 13 | 96% (1-y PFS) | 96% (1-y OS) | 0 | na |
R 2 | Ruan (2015) [60] | 38 | 65(42–86) | 34/34/32 | 92 | 64 | 30 | 85% (2-y PFS) | 97% (2-y OS) | 0 | 23.3 |
R-CHOP+ Zevalin | 56 | 61 (33–83) | 50/27/12 | 74 | 42 | 9.8ys | na | 56% at 10 ys (age ≤ 65) | 0 | 10.7 |